

cyclo

spectrum[®]
PHARMACY PRODUCTS



800.370.6231
SpectrumRx.com

SUGGESTED FORMULA

Ketoprofen 10% / Lidocaine 5% / Cyclobenzaprine 2% / Baclofen 2% in Niosome

Version number: 1.0

Volume: 30gm

Ketoprofen, USP (K1155)	3gm
Lidocaine Hydrochloride, USP (LI103)	1.5gm
Cyclobenzaprine Hydrochloride, USP (C1570)	0.6gm
Baclofen, USP (B1049)	0.6gm
Ethoxy Diglycol, Reagent (E1022)	XmL
Niosome Cream, Heavy (B4506)	30 gm Q.S.

SUGGESTED COMPOUNDING PROCEDURES

1. Triturate all powders together
2. Wet powders with Ethoxy Diglycol until a smooth paste is formed
2. Q.S. with Niosome Cream and mix well
4. Mill all ingredients
5. Check for "grit" by rubbing a small amount on the back of your gloved hand, mill again if necessary

Suggested Quality Assurance Checklist:

% Calculation: _____

No Grit: _____

Correct Auxiliary Labels: _____

Room Temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.

It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date is estimated to be 30 days

*Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

06/18 JD